You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沃森生物(300142.SZ):擬與藍鵲生物開展新冠病毒變異株mRNA疫苗的產品開發及商業化合作
格隆匯 01-28 16:36

格隆匯1月28日丨沃森生物(300142.SZ)宣佈,2022年1月27日,公司第四屆董事會第三十一次會議審議通過了《關於公司簽署新型冠狀病毒變異株mRNA疫苗技術開發及商業化合作協議的議案》,董事會同意公司與上海藍鵲生物醫藥有限公司(簡稱“藍鵲生物”)簽署《新型冠狀病毒變異株mRNA疫苗技術開發及商業化合作協議》,共同開展新型冠狀病毒變異株mRNA疫苗的產品開發及商業化合作。

藍鵲生物在mRNA藥物研發領域具有核心技術優勢,自創建以來一直聚焦mRNA藥物的研究與開發,擁有先進的抗原設計、mRNA序列深度優化、mRNA全流程工藝技術、成熟的LNP包封工藝技術及其檢測方法,並在mRNA藥物關鍵技術和關鍵原輔料如修飾核苷酸、帽子類似物、酶、陽離子脂質上具有自主研發能力。

佈局mRNA新技術、新產品符合公司的長遠發展戰略。為應對新冠病毒的不斷變異,公司在原有新冠疫苗產品開發的基礎上,與合作伙伴聯合開發新冠變異株mRNA疫苗,有利於進一步應對疫情演變和滿足新形勢下疫情防控的需求。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account